Xenitra Limited has secured A$1.5 million through a discounted share placement to accelerate growth in higher-margin OTC medicines, FSMP, and tokenised FMCG sales. The capital will fund inventory expansion, supplier fulfilment, and ecommerce activation as the company shifts from low-margin distribution to a diversified healthcare platform.
- A$1.5 million placement at A$0.003 per share with free-attaching options
- Funds to expand OTC Medicines, FSMP, and OPAL tokenised sales channels
- Initial OTC orders of A$450,000 fulfilled under Kangsheng agreement
- OPAL tokenised sales exceed A$1.5 million with 500+ distributors onboarded
- Latest quarter delivered positive operating cash flow and margin improvement
Capital Raise Targets Higher-Margin Growth
Xenitra Limited (ASX:XEN) has raised A$1.5 million through a placement of 500 million new shares priced at A$0.003 each, representing a 6.25% discount to the recent VWAP. The raise includes free-attaching options exercisable at A$0.004 by April 2028, pending shareholder approval. The company plans to deploy the proceeds to accelerate sales growth across its higher-margin segments: OTC Medicines, Food for Special Medical Purposes (FSMP), and the OPAL tokenised FMCG platform.
This capital injection marks a strategic pivot from Xenitra's previous low-margin distribution model towards a diversified, cross-border healthcare and digital commerce platform. The funds will expand inventory procurement, supplier capacity, order fulfilment, and ecommerce activation, supporting brand and distributor onboarding within established China sales channels.
OTC Medicines Platform Gains Traction
Xenitra’s acquisition of Hong Kong Fukang Trading Co. has established an operational OTC Medicines platform, complete with a Hong Kong pharmaceutical wholesale licence, warehousing, logistics, and an active JD.com storefront. In July 2026, preliminary and unaudited figures show approximately A$450,000 in initial Fukang orders were fulfilled, underpinning early commercial momentum.
The company’s three-year procurement agreement with Kangsheng Pharmaceuticals Hong Kong Group, carrying a minimum A$12 million commitment, provides a scalable pathway for growth. Additional working capital will deepen inventory levels, broaden the online product range, and enable faster conversion of demand into sales under this agreement. This development aligns with Xenitra’s focus on higher-margin pharmaceutical channels and is a key validation of its OTC strategy.
OPAL Tokenised Sales Expand Rapidly
The OPAL platform, which integrates blockchain-enabled tokenised sales into FMCG distribution, has generated over A$1.5 million in product sales and onboarded more than 500 distribution partners within its first quarter. The placement proceeds will support onboarding additional international FMCG brands and distributors, expand product availability, and enhance the ecommerce and tokenisation infrastructure to increase transaction volumes.
OPAL’s tokenised sales model reportedly offers substantially higher margins than Xenitra’s historical nutritionals distribution business, representing a significant commercial opportunity as the company scales this innovative channel.
FSMP Framework Agreement Adds New Growth Channel
Extending its healthcare platform, Xenitra recently announced a framework agreement with Joy Charm targeting A$5 million in procurement of Food for Special Medical Purposes over three years. While the target is not a guaranteed minimum, individual purchase orders will govern sales, pricing, and delivery. The placement funds will enhance Xenitra’s ability to source FSMP products, support supplier and logistics demands, and fulfil purchase orders as this channel develops.
Improved Financials Support Expansion
In the latest reported quarter, Xenitra delivered A$800,000 in positive operating cash flow, a 16% improvement in gross margins, and approximately A$1 million in annualised operating cost savings. This leaner operating platform underpins the company’s commercial execution strategy and provides a foundation for scaling its higher-margin businesses.
Novus Capital Limited acted as Lead Manager for the placement, receiving a 6% cash fee plus 15 million shares and 30 million options subject to shareholder approval. The placement shares are expected to be allotted by 7 September 2026.
Chairman Dr Anthony Noble emphasised that the raise is focused on execution; converting existing agreements, channels, and customer demand into rapidly growing, higher-margin sales. The company’s strategic reset and disciplined cash management appear to be bearing fruit as Xenitra moves beyond setup into commercial delivery.
Bottom Line?
Xenitra’s capital raise aims to fund a crucial scaling phase for its higher-margin OTC, FSMP, and tokenised FMCG businesses, but execution risks remain as agreements convert into sustained revenue streams.
Questions in the middle?
- Will shareholder approval for the placement options and lead manager securities proceed smoothly?
- How quickly can Xenitra convert the Kangsheng and Joy Charm agreements into consistent, profitable sales?
- Can OPAL’s tokenised sales momentum sustain growth beyond its initial launch quarter?